1-minute AI diabetic eye exam ​at any point of care
The only FDA-cleared solution providing instant AI diagnosis using handheld or tabletop cameras
AEYE Diagnostic Screening
AEYE-DS utilizes Artificial Intelligence (AI) technology to instantly diagnose diabetic retinopathy from retinal images
.jpg){kind=small}
.png)
First to be cleared with both a desktop camera and a portable handheld camera
_edited.png)
AEYE with TOPCON
See the AEYE-DS
with Topcon in Action
See the AEYE-DS
with Aurora in Action
Best-in-class Accuracy
.png)
The only solution to be proven accurate in clinical trials on both desktop and handheld cameras
Desktop
91%
Specificity
93%
Sensitivity
Handheld
89%-94%
Specificity
92%-93%
Sensitivity
1-minute Screening
The only AI that requires only 1 image per eye, and rarely requires dilation
1 min
exam avg.
Instant
Diagnostic report
>99%
Imageability
.png)
Closes Care Gaps
Enables point-of-care screening instead of referring to a specialist
CPT 92229
Reimbursement Code
Measure 117
HEDIS Quality Measure
Over 40M
people with diabetes in the US and 500M worldwide are at risk of sight-threatening diabetic retinopathy.
85%
of people over 40 with diabetes will develop diabetic retinopathy.
Why it matters
Screening Prevents Blindness
Accessible and affordable screening for diabetic retinopathy is vital to help ensure patients with diabetes receive sight-saving treatment.
Only 15% to 50%
of patients with diabetes in the US adhere to the recommended screening.
Closing care gaps
Replacing specialist screening with AI diagnosis
Using AI technology, primary care physicians can screen for diabetic retinopathy on the spot, replacing specialist referrals and closing the diabetic retinopathy care gap
Before
After
Benefits of Point-of-Care Screening
_edited.png)
Reimbursable
Dedicated CPT code 92229 for AI diabetic retinopathy screening
Closes Care Gaps
Closes the care diabetic eye gap, improving HEDIS scores and and Star ratings
Advantages of AEYE-DS
Accessible
Enables point of care screenings anywhere, whether at home or in-clinic
_edited.png)
1-minute Screening
Requires only one image per eye; rarely requires dilation; producing instant diagnosis
See what people are saying about us
The time has finally come for autonomous screening technology to exceed the efficacy of the human expert. The implications are that it can be practical for deployment on the front lines of population health – the primary care offices, where over 99% imageability and single image diagnostic acquisition are tantamount to market success
Sean Ianchulev
MD, MPH, CEO at Eyenovia. Professor of Ophthalmology at UCSF & Mt. Sinai
Our Research
Autonomous comprehensive diagnostic screening for a broad range of diseases using retinal images
